Background: Post-stroke neuropathic pain, particularly central post-stroke pain and facial pain syndromes, continues to be challenging to manage with conventional pharmacological approaches. While botulinum toxin A (BoNT-A) is well established for treating spasticity after stroke, its use in the management of central neuropathic pain remains less well established. Methods: This report presents two cases of patients with refractory neuropathic pain following ischemic cerebrovascular accidents who achieved significant pain relief through subcutaneous botulinum toxin administration, after failure of multiple conventional and intramuscular BoNT-A approaches. Results: Case 1 involves a 66-year-old patient with 18 years of post-stroke hemicorporeal pain who responded dramatically to subcutaneous BoNT-A injections after extensive prior treatment failures. Case 2 describes a 54-year-old with trigeminal-region and mandibular pain following ICA dissection who achieved complete pain resolution at facial sites with subcutaneous administration of BoNT-A. Conclusions: These cases demonstrate the potential efficacy of subcutaneous botulinum toxin for managing post-stroke neuropathic pain in selected patients and suggest a mechanism of action related to peripheral pain sensitization rather than motor denervation. Our findings support further investigation of subcutaneous administration techniques for pain management in specialized centers.
Building similarity graph...
Analyzing shared references across papers
Loading...
Stefano Carda
Elisa Grana
Toxins
University of Lausanne
University Hospital of Lausanne
Spectra Energy (Canada)
Building similarity graph...
Analyzing shared references across papers
Loading...
Carda et al. (Sun,) studied this question.
www.synapsesocial.com/papers/69fadb0b03f892aec9b1e93b — DOI: https://doi.org/10.3390/toxins18050217
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: